This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Innate Pharma. Active years: 2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2014
Title: Youness Amharar: Innovator in Pharmaceutical Composition
Introduction
Youness Amharar is a notable inventor based in Rouen, France. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on polymorphic forms of chemical compounds. His expertise and dedication to research have led to the development of valuable inventions that can impact the pharmaceutical industry.
Latest Patents
Youness Amharar holds a patent for a novel invention titled "Polymorphic form of CHDMAPP, method of preparation thereof, and pharmaceutical composition comprising same." This invention relates to new polymorphs of (2E)-1-hydroxy-2-methylpent-2-enyl-pyrophosphonate disodium (CHDMAPP-Na), detailing the process for preparing these polymorphs and the pharmaceutical compositions that contain them. He has 1 patent to his name, showcasing his innovative approach to pharmaceutical development.
Career Highlights
Youness Amharar is currently associated with Innate Pharma, a company dedicated to advancing cancer therapies. His role at the company allows him to apply his research skills and contribute to the development of groundbreaking treatments. His work is characterized by a commitment to improving patient outcomes through innovative pharmaceutical solutions.
Collaborations
Youness collaborates with talented professionals in his field, including colleagues such as Guillaume Descamps and Yohann Cartigny. These collaborations enhance the research environment and foster the exchange of ideas, leading to more effective innovations in pharmaceutical compositions.
Conclusion
Youness Amharar is a distinguished inventor whose work in pharmaceutical compositions is paving the way for advancements in cancer treatment. His dedication to research and innovation continues to make a significant impact in the field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
